90 related articles for article (PubMed ID: 23733674)
21. Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Lin JT; Lai GM; Chang TH; Liu MT; Bi CP; Wang JW; Chen MK
Adv Ther; 2012 Jan; 29(1):71-7. PubMed ID: 22161550
[TBL] [Abstract][Full Text] [Related]
22. Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
Billan S; Kaidar-Person O; Atrash F; Doweck I; Haim N; Kuten A; Ronen O
Isr Med Assoc J; 2013 May; 15(5):231-5. PubMed ID: 23841243
[TBL] [Abstract][Full Text] [Related]
23. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus.
Ui T; Fujii H; Hosoya Y; Nagase M; Mieno MN; Mori M; Zuiki T; Saito S; Kurashina K; Haruta H; Matsumoto S; Niki T; Lefor A; Yasuda Y
Dis Esophagus; 2015; 28(2):180-7. PubMed ID: 24529073
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
[TBL] [Abstract][Full Text] [Related]
25. Nimotuzumab plus chemotherapy with docetaxel, cisplatin, 5-fluorouracil for locally advanced head and neck squamous cell carcinoma: A clinical study.
Wang X; Gu J; Shao C; Han K; Meng J
J Cancer Res Ther; 2019; 15(2):312-316. PubMed ID: 30964103
[TBL] [Abstract][Full Text] [Related]
26. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
Kilickap S; Yalcin S; Ates O; Tekuzman G
Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
Bae WK; Hwang JE; Shim HJ; Cho SH; Lee JK; Lim SC; Chung WK; Chung IJ
Cancer Chemother Pharmacol; 2010 Feb; 65(3):589-95. PubMed ID: 19830427
[TBL] [Abstract][Full Text] [Related]
28. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
30. A modified DCF regimen as primary treatment for patients with metastatic gastric cancer.
Koca D; Dogan E; Yardim H; Duzen O; Karaca S
J BUON; 2013; 18(2):377-84. PubMed ID: 23818349
[TBL] [Abstract][Full Text] [Related]
31. Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer.
Yamamoto K; Fujiwara Y; Nishida T; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Mori M; Doki Y
Anticancer Res; 2009 Oct; 29(10):4211-5. PubMed ID: 19846975
[TBL] [Abstract][Full Text] [Related]
32. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
Fonseca E; Grau JJ; Sastre J; García-Gómez JM; Rueda A; Pastor M; Lara MA; Navalón M; Berrocal A; Tisaire JL; Cruz JJ
Eur J Cancer; 2005 Jun; 41(9):1254-60. PubMed ID: 15908196
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.
Oh DY; Kim TY; Kwon JH; Lee JJ; Joh Y; Kim DW; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2005 Jul; 35(7):380-5. PubMed ID: 15976069
[TBL] [Abstract][Full Text] [Related]
34. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Yamasaki M; Miyata H; Tanaka K; Shiraishi O; Motoori M; Peng YF; Yasuda T; Yano M; Shiozaki H; Mori M; Doki Y
Oncology; 2011; 80(5-6):307-13. PubMed ID: 21778771
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
González-Larriba JL; Garcia Carbonero I; Sastre Valera J; Perez Segura P; Diaz-Rubio E
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):90-7. PubMed ID: 9348577
[TBL] [Abstract][Full Text] [Related]
36. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
37. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
[TBL] [Abstract][Full Text] [Related]
39. Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study.
Tsuchiya Y; Ushijima K; Noguchi T; Okada N; Hayasaka JI; Jinbu Y; Ando H; Mori Y; Kusama M; Fujimura A
Chronobiol Int; 2018 Feb; 35(2):289-294. PubMed ID: 29144178
[TBL] [Abstract][Full Text] [Related]
40. [Weekly dosage of docetaxel combined with cisplatin and 5-fluorouracil in the treatment of advanced gastric cancer].
Zhang AM; Ye S
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1555-7. PubMed ID: 17959535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]